Lufax Faces Class Action Lawsuit Amid Stock Plunge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy LU?
Source: Globenewswire
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Lufax, alleging securities fraud and other unlawful business practices by the company and its executives, with investors needing to apply as Lead Plaintiff by May 20, 2026, highlighting serious governance concerns.
- Auditor Change Controversy: On January 27, 2025, Lufax announced plans to replace its auditor, PricewaterhouseCoopers, due to significant concerns regarding the company's financial disclosures for 2022 and 2023, leading to a substantial decline in investor confidence regarding financial transparency.
- Stock Price Volatility: Following the auditor change announcement, Lufax's American Depositary Share price fell nearly 22% over three trading sessions, reflecting extreme market concerns about the company's financial health and potential legal risks.
- Law Firm Background: Pomerantz LLP is a renowned securities class action law firm with over 85 years of experience, focusing on advocating for victims of securities fraud, indicating the potential for widespread attention and significant damages in this case.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LU?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LU
About LU
LUFAX HOLDING LTD is a holding company mainly engaged in providing financial services for small and micro enterprises. The Company's core retail credit enablement business includes bank-funded loans, trust-funded loans and consumer finance loans. The Company is also engaged in wealth management and providing access to financial products and services. The Company conducts the business through its subsidiaries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lufax Faces Class Action Lawsuit for Securities Fraud
- Class Action Reminder: The Schall Law Firm alerts investors that Lufax is facing a class action lawsuit for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities transactions between April 7, 2023, and January 26, 2025, with a deadline for investor contact set for May 20, 2026.
- False Statements Allegation: The complaint alleges that Lufax made false and misleading statements during the class period, failed to maintain adequate internal controls, and materially misstated financial results, leading to investor losses when the truth emerged.
- Legal Proceedings Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs; those who take no action will remain absent class members and may miss out on potential recovery.
- Investor Rights Advocacy: The Schall Law Firm specializes in securities class action lawsuits and encourages affected investors to reach out to discuss their rights, demonstrating the firm's commitment to providing legal support and protecting investor interests worldwide.
See More
Lufax Faces Securities Class Action Lawsuit
- Lawsuit Background: Lufax (NYSE:LU) is facing a class action lawsuit for securities transactions between April 7, 2023, and January 26, 2025, alleging undisclosed related-party transactions that resulted in significant investor losses.
- Auditor Dismissal: On January 27, 2025, Lufax announced the removal of PricewaterhouseCoopers as its auditor due to concerns over undisclosed related-party transactions, triggering a nearly 14% drop in share price.
- Lack of Internal Controls: The class action complaint alleges that Lufax lacked adequate internal controls and that its financial statements were materially misstated, severely undermining investor confidence in the company's financial transparency.
- Investigation and Consequences: Hagens Berman is investigating whether Lufax intentionally violated accounting rules, and if proven, this could lead to broader legal liabilities and financial repercussions for the company.
See More
Lufax Faces Class Action Lawsuit, Shares Plunge 14%
- Class Action Filed: A securities class action lawsuit has been initiated against Lufax (NYSE: LU) to represent investors who acquired its securities between April 7, 2023, and January 26, 2025, highlighting significant investor concerns regarding the company's financial transparency.
- Auditor Dismissal: On January 27, 2025, Lufax announced the dismissal of PricewaterhouseCoopers as its auditor due to concerns over undisclosed related-party transactions, resulting in a nearly 14% drop in share price that day, indicating a loss of market confidence in the company's governance.
- Financial Reporting Allegations: The class action alleges that Lufax lacked adequate internal controls and materially misstated its financial results, with investors learning the truth on January 27, 2025, prompting a swift market reaction that intensified doubts about the company's financial health.
- Complex Transactions Revealed: On April 23, 2025, Lufax disclosed its involvement as the sole investor in certain trusts from May 2023 to June 2024, engaging in complex transactions that led to overstated assets and liabilities, further triggering an in-depth investigation into its compliance practices.
See More
Lufax Faces Class Action Lawsuit for Investor Losses
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against Lufax in the Central District of California, representing investors who purchased Lufax securities between April 7, 2023, and January 26, 2025, indicating significant legal risks for the company.
- Allegation Details: The lawsuit alleges that Lufax lacked adequate internal controls and materially misstated financial results during the class period, misleading investors about the company's business and prospects, which could lead to substantial financial losses.
- Investor Rights Protection: Investors must apply by May 20, 2026, to be appointed as lead plaintiffs in the lawsuit, highlighting the importance of protecting investor rights and potentially impacting future investment decisions.
- Legal Consultation Available: Bragar Eagel & Squire offers no-cost legal consultations, encouraging affected investors to contact attorneys for more information, demonstrating a commitment to safeguarding investor interests.
See More
Multiple Companies Face Class Action Lawsuits
- Lufax Class Action: Lufax Holding Ltd. is facing allegations for failing to disclose inadequate internal controls and misstated financial results during the period from April 7, 2023, to January 26, 2025, which undermines investor confidence due to misleading positive statements about the company's prospects.
- Atara Biotherapeutics Lawsuit: Atara Biotherapeutics, Inc. is accused of not disclosing manufacturing issues and clinical trial risks from May 20, 2024, to January 9, 2026, potentially overstating the likelihood of FDA approval for its product, which could significantly impact the company's financial condition.
- Coty Legal Issues: Coty Inc. is under scrutiny for failing to reveal underperformance in its Consumer Beauty segment and slowing market growth from November 5, 2025, to February 4, 2026, leading to misleading positive statements about its business operations and prospects, which may affect investor trust.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz remind investors who suffered losses during the specified periods to reach out for legal rights discussions, emphasizing the firm's commitment to protecting investor interests.
See More
Reminder of Lufax Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Lufax securities between April 7, 2023, and January 26, 2025, that they must apply to be lead plaintiff by May 20, 2026, to participate in the class action, as failing to do so will forfeit their opportunity to represent other investors.
- Fee Arrangement: Investors participating in the lawsuit will not incur any upfront costs, as the law firm operates on a contingency fee basis, meaning investors bear no financial burden until compensation is secured, thus lowering the barrier for investor participation.
- Lawsuit Background: The lawsuit alleges that Lufax made false or misleading statements during the class period, failing to disclose inadequate internal controls and materially misstated financial results, which led to investor losses when the truth emerged, potentially impacting the company's reputation and future financing capabilities.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company, recovering over $438 million for investors in 2019 alone, demonstrating its expertise and influence in such cases.
See More
Lufax Faces Class Action Lawsuit for Securities Fraud
- Class Action Reminder: The Schall Law Firm alerts investors that Lufax is facing a class action lawsuit for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities transactions between April 7, 2023, and January 26, 2025, with a deadline for investor contact set for May 20, 2026.
- False Statements Allegation: The complaint alleges that Lufax made false and misleading statements during the class period, failed to maintain adequate internal controls, and materially misstated financial results, leading to investor losses when the truth emerged.
- Legal Proceedings Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs; those who take no action will remain absent class members and may miss out on potential recovery.
- Investor Rights Advocacy: The Schall Law Firm specializes in securities class action lawsuits and encourages affected investors to reach out to discuss their rights, demonstrating the firm's commitment to providing legal support and protecting investor interests worldwide.
See More
Lufax Faces Securities Class Action Lawsuit
- Lawsuit Background: Lufax (NYSE:LU) is facing a class action lawsuit for securities transactions between April 7, 2023, and January 26, 2025, alleging undisclosed related-party transactions that resulted in significant investor losses.
- Auditor Dismissal: On January 27, 2025, Lufax announced the removal of PricewaterhouseCoopers as its auditor due to concerns over undisclosed related-party transactions, triggering a nearly 14% drop in share price.
- Lack of Internal Controls: The class action complaint alleges that Lufax lacked adequate internal controls and that its financial statements were materially misstated, severely undermining investor confidence in the company's financial transparency.
- Investigation and Consequences: Hagens Berman is investigating whether Lufax intentionally violated accounting rules, and if proven, this could lead to broader legal liabilities and financial repercussions for the company.
See More
Lufax Faces Class Action Lawsuit, Shares Plunge 14%
- Class Action Filed: A securities class action lawsuit has been initiated against Lufax (NYSE: LU) to represent investors who acquired its securities between April 7, 2023, and January 26, 2025, highlighting significant investor concerns regarding the company's financial transparency.
- Auditor Dismissal: On January 27, 2025, Lufax announced the dismissal of PricewaterhouseCoopers as its auditor due to concerns over undisclosed related-party transactions, resulting in a nearly 14% drop in share price that day, indicating a loss of market confidence in the company's governance.
- Financial Reporting Allegations: The class action alleges that Lufax lacked adequate internal controls and materially misstated its financial results, with investors learning the truth on January 27, 2025, prompting a swift market reaction that intensified doubts about the company's financial health.
- Complex Transactions Revealed: On April 23, 2025, Lufax disclosed its involvement as the sole investor in certain trusts from May 2023 to June 2024, engaging in complex transactions that led to overstated assets and liabilities, further triggering an in-depth investigation into its compliance practices.
See More
Lufax Faces Class Action Lawsuit for Investor Losses
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against Lufax in the Central District of California, representing investors who purchased Lufax securities between April 7, 2023, and January 26, 2025, indicating significant legal risks for the company.
- Allegation Details: The lawsuit alleges that Lufax lacked adequate internal controls and materially misstated financial results during the class period, misleading investors about the company's business and prospects, which could lead to substantial financial losses.
- Investor Rights Protection: Investors must apply by May 20, 2026, to be appointed as lead plaintiffs in the lawsuit, highlighting the importance of protecting investor rights and potentially impacting future investment decisions.
- Legal Consultation Available: Bragar Eagel & Squire offers no-cost legal consultations, encouraging affected investors to contact attorneys for more information, demonstrating a commitment to safeguarding investor interests.
See More
Multiple Companies Face Class Action Lawsuits
- Lufax Class Action: Lufax Holding Ltd. is facing allegations for failing to disclose inadequate internal controls and misstated financial results during the period from April 7, 2023, to January 26, 2025, which undermines investor confidence due to misleading positive statements about the company's prospects.
- Atara Biotherapeutics Lawsuit: Atara Biotherapeutics, Inc. is accused of not disclosing manufacturing issues and clinical trial risks from May 20, 2024, to January 9, 2026, potentially overstating the likelihood of FDA approval for its product, which could significantly impact the company's financial condition.
- Coty Legal Issues: Coty Inc. is under scrutiny for failing to reveal underperformance in its Consumer Beauty segment and slowing market growth from November 5, 2025, to February 4, 2026, leading to misleading positive statements about its business operations and prospects, which may affect investor trust.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz remind investors who suffered losses during the specified periods to reach out for legal rights discussions, emphasizing the firm's commitment to protecting investor interests.
See More
Reminder of Lufax Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Lufax securities between April 7, 2023, and January 26, 2025, that they must apply to be lead plaintiff by May 20, 2026, to participate in the class action, as failing to do so will forfeit their opportunity to represent other investors.
- Fee Arrangement: Investors participating in the lawsuit will not incur any upfront costs, as the law firm operates on a contingency fee basis, meaning investors bear no financial burden until compensation is secured, thus lowering the barrier for investor participation.
- Lawsuit Background: The lawsuit alleges that Lufax made false or misleading statements during the class period, failing to disclose inadequate internal controls and materially misstated financial results, which led to investor losses when the truth emerged, potentially impacting the company's reputation and future financing capabilities.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company, recovering over $438 million for investors in 2019 alone, demonstrating its expertise and influence in such cases.
See More
